Press release
Leading Companies Enhancing Their Presence in the Chronic Hepatitis B Market
Chronic Hepatitis B Market
Anticipated Market Size of the Chronic Hepatitis B Industry by 2030
The chronic hepatitis B market is projected to grow steadily, reaching a valuation of $4.74 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 3.7%. The forecast growth stems from increased investments in next-generation HBV treatments, heightened demand for treatment regimens that have a finite duration, and advancements in therapeutic vaccine development. Additionally, the focus on eliminating viral reservoirs and the intensification of global hepatitis elimination programs contribute significantly to this upward trajectory. Key patterns expected to influence the market include wider adoption of long-term antiviral therapies, progress in functional cure research, heightened emphasis on early detection and disease monitoring, the growth of immune-modulating treatment approaches, and improved patient adherence initiatives.
Download a free sample of the chronic hepatitis b market report:
https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Driving the Chronic Hepatitis B Market Forward
A number of prominent pharmaceutical companies hold significant positions within the chronic hepatitis B market. These include Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, and Nucorion Pharmaceuticals.
Strategic Acquisition Strengthens GSK's Position in Hepatitis B Treatment
In a strategic move in November 2023, GlaxoSmithKline plc, headquartered in the United Kingdom, secured exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. This acquisition includes JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug aimed at enhancing GSK's portfolio in chronic hepatitis B treatments. Janssen Pharmaceuticals, a Belgian branch of Johnson & Johnson, is recognized for its focus on developing therapies for complex diseases, including infectious diseases such as chronic hepatitis B. This deal is expected to reinforce GSK's foothold in this therapeutic area with the addition of a promising new treatment option.
The chronic hepatitis B sector is progressing steadily, driven by advances in treatment options and ongoing research efforts. As new therapies and strategies emerge, the market is poised for consistent expansion over the coming years. Below is a detailed overview of the market size projections, major players, key trends, and segment analysis shaping this important healthcare industry.
Anticipated Market Size of the Chronic Hepatitis B Industry by 2030
The chronic hepatitis B market is projected to grow steadily, reaching a valuation of $4.74 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 3.7%. The forecast growth stems from increased investments in next-generation HBV treatments, heightened demand for treatment regimens that have a finite duration, and advancements in therapeutic vaccine development. Additionally, the focus on eliminating viral reservoirs and the intensification of global hepatitis elimination programs contribute significantly to this upward trajectory. Key patterns expected to influence the market include wider adoption of long-term antiviral therapies, progress in functional cure research, heightened emphasis on early detection and disease monitoring, the growth of immune-modulating treatment approaches, and improved patient adherence initiatives.
Download a free sample of the chronic hepatitis b market report:
https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Driving the Chronic Hepatitis B Market Forward
A number of prominent pharmaceutical companies hold significant positions within the chronic hepatitis B market. These include Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, and Nucorion Pharmaceuticals.
Strategic Acquisition Strengthens GSK's Position in Hepatitis B Treatment
In a strategic move in November 2023, GlaxoSmithKline plc, headquartered in the United Kingdom, secured exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. This acquisition includes JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug aimed at enhancing GSK's portfolio in chronic hepatitis B treatments. Janssen Pharmaceuticals, a Belgian branch of Johnson & Johnson, is recognized for its focus on developing therapies for complex diseases, including infectious diseases such as chronic hepatitis B. This deal is expected to reinforce GSK's foothold in this therapeutic area with the addition of a promising new treatment option.
Emerging Trends Emphasizing Home-Based Healthcare Solutions
There is a growing emphasis among companies in the digital hydration reminder and urinalysis strip markets on creating home-based healthcare technologies. These solutions provide users with convenient, real-time monitoring of hydration levels and health biomarkers, enhancing personalized healthcare management. By enabling early detection of potential health concerns, these innovations support improved wellness outcomes.
A notable example of this trend is from January 2024, when Vivoo, a US-based health-tech firm specializing in at-home diagnostics, launched an advanced at-home digital Urinary Tract Infection (UTI) testing kit at CES 2024. The product allows users to conduct tests quickly by scanning a urine strip through the Vivoo app, which employs artificial intelligence to deliver accurate results and share data with healthcare providers. This innovation facilitates easier home monitoring and better healthcare accessibility.
Segment Analysis and Market Share Overview in the Global Chronic Hepatitis B Market
This report categorizes the chronic hepatitis B market across various segments for a comprehensive understanding:
1) Drug Class: Antivirals and Immune Modulators
2) Gender: Male and Female
3) Distribution Channels: Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Providers
Further subsegments include:
- Antivirals: Nucleos(t)ide Analogs such as Tenofovir and Entecavir, and Interferons including Pegylated Interferon
- Immune Modulators: Immune Checkpoint Inhibitors and Therapeutic Vaccines, including HBV vaccines currently in development
These detailed classifications offer a clear picture of the market's structure and growth prospects.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leading Companies Enhancing Their Presence in the Chronic Hepatitis B Market here
News-ID: 4464449 • Views: …
More Releases from The Business Research Company
Global Factors Influencing the Rapid Evolution of the Chronic Pulmonary Hyperten …
The chronic pulmonary hypertension treatment sector is positioned for notable expansion as advancements in therapies and patient management gain momentum. With several innovative drugs entering the market and shifts toward more personalized care, the industry is set to witness significant growth over the coming years. Let's explore the market's size projections, key players, influential trends, and segment breakdowns shaping this evolving field.
Projected Market Size and Growth Trajectory for Chronic Pulmonary…
Market Structure, Emerging Trends, and Key Player Analysis of the Chronic Obstru …
The use of virtual reality (VR) in treating chronic obstructive pulmonary disease (COPD) is gaining significant attention as a promising approach to respiratory therapy. With technological advancements and rising interest in digital healthcare solutions, this sector is set for strong growth in the coming years. Let's explore the market size, key players, driving factors, and notable trends shaping this emerging industry.
Market Size Outlook and Expansion Potential of the COPD Virtual…
Global Drivers Analysis: The Rapid Evolution of the Chondroplasty Market
The chondroplasty market is gaining significant attention as advancements in orthopedic treatments and an aging population drive demand for effective joint care solutions. This sector is set for robust expansion, driven by innovative techniques and growing interest in minimally invasive procedures. Let's explore the market's valuation, key players, emerging trends, and the segmentation that shapes its landscape.
Forecasted Growth and Valuation of the Chondroplasty Market by 2030
The chondroplasty market is…
Chlamydia Infection Treatment Market Overview, Emerging Trends, and Key Player A …
The treatment landscape for chlamydia infections is on the verge of notable expansion, driven by advancements in medical technology and evolving healthcare practices. With increasing emphasis on effective therapies and integrated diagnostic approaches, this sector is set to experience significant growth in the coming years. Let's explore the market's expected value, influential players, current trends, and key segments shaping its future.
Projected Market Value and Growth Prospects for the Chlamydia Infection…
More Releases for Pharma
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva …
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
